Amgen (AMGN) Stock Forecast & Price Target

Compare

6,606 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AMGN Analyst Ratings

Moderate Buy

9 Buy

11 Hold

1 Sell

Based on 21 analysts giving stock ratings to

Amgen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AMGN Stock 12 Month Forecast

Average Price Target

$323.47

▲(15.45% Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Amgen in the last 3 months. The average price target is $323.47 with a high forecast of $405.00 and a low forecast of $272.00. The average price target represents a 15.45% change from the last price of $280.19.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"253":"$253","406":"$406","291.25":"$291.3","329.5":"$329.5","367.75":"$367.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":405,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$405.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":323.47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$323.47</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":272,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$272.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[253,291.25,329.5,367.75,406],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,286.92,296.00307692307695,305.0861538461539,314.1692307692308,323.2523076923077,332.3353846153846,341.41846153846154,350.5015384615385,359.5846153846154,368.6676923076923,377.75076923076927,386.83384615384614,395.91692307692307,{"y":405,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,286.92,289.7315384615385,292.54307692307697,295.3546153846154,298.16615384615386,300.97769230769234,303.7892307692308,306.60076923076923,309.4123076923077,312.2238461538462,315.03538461538466,317.8469230769231,320.65846153846155,{"y":323.47,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,286.92,285.7723076923077,284.6246153846154,283.4769230769231,282.3292307692308,281.1815384615385,280.0338461538462,278.88615384615383,277.73846153846154,276.59076923076924,275.44307692307694,274.2953846153846,273.1476923076923,{"y":272,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":323.03,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":309.96,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":308.89,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":271.25,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":254.22,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":278.39,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.9,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":301.78,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":279.03,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":286.15,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":288.18,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":294.49,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":286.92,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$405.00

Average Price Target$323.47

Lowest Price Target$272.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Vamil Divan

Guggenheim

$288

Hold

2.79%

Upside

Reiterated

09/05/25

Amgen (AMGN) Gets a Hold from Guggenheim

Christopher Raymond

Raymond James

―

Hold

―

Reiterated

09/04/25

Amgen assumed with a Market Perform at Raymond JamesAmgen assumed with a Market Perform at Raymond James

Matt Phipps

William Blair

―

Buy

―

Reiterated

09/03/25

Amgen's Strategic Focus and Portfolio Strength Justify Buy Rating Despite Bemarituzumab Challenges4:04 PM Research | Healthcare Amgen Inc. (AMGN) $283.18 Market Value (M): $152,453 Biotechnology Matt Phipps, Ph.D.

David Amsellem

Piper Sandler

$342

Buy

22.06%

Upside

Reiterated

08/28/25

Piper Sandler Keeps Their Buy Rating on Amgen (AMGN)

Veda Pharmyne

TR | OpenAI - 4o

$317

Hold

13.14%

Upside

Reiterated

08/26/25

AI Generated ArticleAI Generated Article

David Risinger

Leerink Partners

―

Hold

―

Reiterated

08/25/25

Amgen's Repatha: Balancing Growth Potential with Long-Term RisksWe project sales to ramp relative to consensus as follows: 2025E $2.8B vs. $2.8B ramping to 2028E $4.2B vs. $3.9B (consensus source is Visible Alpha). For 2029E, we project $3.9B (down $300M from our ‘28E) vs. cons’ $4.0B, but our revenue decline forecast may not reflect enough downside price control risk; note that we expect Repatha to face Medicare Part D IRA price controls in 2029. Please refer to our recent reports on IRA price controls (May 28, 2025 report Next IRA Targets: 2028 & 2029 2025 report: Updated IRA Tables). In addition, we see risk of biosimilar competition after LOEs occur. Repatha’s composition of matter expiration in the US is on Europe is on Aug 22, 2028. But there are methods of treatment and formulation patents that may offer protection to 2032-2033. See Exhibit 1.

Salim Syed

Mizuho Securities

$280

Hold

-0.07%

Downside

Reiterated

08/18/25

Mizuho Securities Keeps Their Hold Rating on Amgen (AMGN)

Courtney Breen

Bernstein

$335

Buy

19.56%

Upside

Reiterated

08/17/25

We rate LLY, GILD, AMGN Outperform.

Carter Gould

Cantor Fitzgerald

$305

Hold

8.85%

Upside

Reiterated

08/13/25

Cantor Fitzgerald Reaffirms Their Hold Rating on Amgen (AMGN)Cantor Fitzgerald analyst Carter Gould reiterated a Neutral rating and $305.00 price target on Amgen (NASDAQ: AMGN).

Yaron Werber

TD Cowen

$389

Buy

38.83%

Upside

Reiterated

08/06/25

Amgen: Strong Financial Performance and Promising Growth Prospects Drive Buy Rating

Trung Huynh

UBS

$326→$317

Hold

13.14%

Upside

Reiterated

08/06/25

Amgen price target lowered to $317 from $326 at UBSAmgen price target lowered to $317 from $326 at UBS

Tim Anderson

Bank of America Securities

$261→$272

Sell

-2.92%

Downside

Reiterated

08/06/25

Amgen's Underperform Rating: Concerns Over R&D Expenses and Trial Strategy Impacting Future Growth

Mohit Bansal

Wells Fargo

$335→$280

Hold

-0.07%

Downside

Reiterated

08/06/25

Amgen (AMGN) Receives a Hold from Wells Fargo

Salveen Richter

Goldman Sachs

$400→$405

Buy

44.54%

Upside

Reiterated

08/06/25

Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (NASDAQ: PRCT), Amgen (NASDAQ: AMGN) and Qiagen (NYSE: QGEN)

Terence Flynn

Morgan Stanley

$330→$333

Hold

18.85%

Upside

Reiterated

08/06/25

Amgen (AMGN) Receives a Hold from Morgan Stanley

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Vamil Divan

Guggenheim

$288

Hold

2.79%

Upside

Reiterated

09/05/25

Amgen (AMGN) Gets a Hold from Guggenheim

Christopher Raymond

Raymond James

―

Hold

―

Reiterated

09/04/25

Amgen assumed with a Market Perform at Raymond JamesAmgen assumed with a Market Perform at Raymond James

Matt Phipps

William Blair

―

Buy

―

Reiterated

09/03/25

David Amsellem

Piper Sandler

$342

Buy

22.06%

Upside

Reiterated

08/28/25

Piper Sandler Keeps Their Buy Rating on Amgen (AMGN)

Veda Pharmyne

TR | OpenAI - 4o

$317

Hold

13.14%

Upside

Reiterated

08/26/25

AI Generated ArticleAI Generated Article

David Risinger

Leerink Partners

―

Hold

―

Reiterated

08/25/25

Salim Syed

Mizuho Securities

$280

Hold

-0.07%

Downside

Reiterated

08/18/25

Mizuho Securities Keeps Their Hold Rating on Amgen (AMGN)

Courtney Breen

Bernstein

$335

Buy

19.56%

Upside

Reiterated

08/17/25

We rate LLY, GILD, AMGN Outperform.

Carter Gould

Cantor Fitzgerald

$305

Hold

8.85%

Upside

Reiterated

08/13/25

Cantor Fitzgerald Reaffirms Their Hold Rating on Amgen (AMGN)Cantor Fitzgerald analyst Carter Gould reiterated a Neutral rating and $305.00 price target on Amgen (NASDAQ: AMGN).

Yaron Werber

TD Cowen

$389

Buy

38.83%

Upside

Reiterated

08/06/25

Amgen: Strong Financial Performance and Promising Growth Prospects Drive Buy Rating

Trung Huynh

UBS

$326→$317

Hold

13.14%

Upside

Reiterated

08/06/25

Amgen price target lowered to $317 from $326 at UBSAmgen price target lowered to $317 from $326 at UBS

Tim Anderson

Bank of America Securities

$261→$272

Sell

-2.92%

Downside

Reiterated

08/06/25

Amgen's Underperform Rating: Concerns Over R&D Expenses and Trial Strategy Impacting Future Growth

Mohit Bansal

Wells Fargo

$335→$280

Hold

-0.07%

Downside

Reiterated

08/06/25

Amgen (AMGN) Receives a Hold from Wells Fargo

Salveen Richter

Goldman Sachs

$400→$405

Buy

44.54%

Upside

Reiterated

08/06/25

Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (NASDAQ: PRCT), Amgen (NASDAQ: AMGN) and Qiagen (NYSE: QGEN)

Terence Flynn

Morgan Stanley

$330→$333

Hold

18.85%

Upside

Reiterated

08/06/25

Amgen (AMGN) Receives a Hold from Morgan Stanley

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Amgen

1 Month

xxx

Success Rate

21/40 ratings generated profit

Average Return

+0.74%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 52.50% of your transactions generating a profit, with an average return of +0.74% per trade.

3 Months

xxx

Success Rate

24/40 ratings generated profit

Average Return

+4.23%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +4.23% per trade.

1 Year

Yaron WerberTD Cowen

Success Rate

28/40 ratings generated profit

Average Return

+10.74%

reiterated a buy rating last month

Copying Yaron Werber's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +10.74% per trade.

2 Years

xxx

Success Rate

29/40 ratings generated profit

Average Return

+11.88%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 72.50% of your transactions generating a profit, with an average return of +11.88% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AMGN Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AMGN has received 22 Buy Ratings, 21 Hold Ratings, and 2 Sell Ratings. AMGN average Analyst price target in the past 3 months is 323.47.

Each month's total comprises the sum of three months' worth of ratings.

AMGN Financial Forecast

AMGN Earnings Forecast

Next quarter’s earnings estimate for AMGN is $5.04 with a range of $4.20 to $5.46. The previous quarter’s EPS was $6.02. AMGN beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 32.86% of the time in the same period. In the last calendar year AMGN has Outperformed its overall industry.

AMGN Sales Forecast

Next quarter’s sales forecast for AMGN is $8.98B with a range of $8.78B to $9.20B. The previous quarter’s sales results were $9.17B. AMGN beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 48.20% of the time in the same period. In the last calendar year AMGN has Outperformed its overall industry.

AMGN Stock Forecast FAQ

What is AMGN’s average 12-month price target, according to analysts?

Based on analyst ratings, Amgen Inc’s 12-month average price target is 323.47.

What is AMGN’s upside potential, based on the analysts’ average price target?

Amgen Inc has 15.45% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AMGN a Buy, Sell or Hold?

Amgen Inc has a consensus rating of Moderate Buy which is based on 9 buy ratings, 11 hold ratings and 1 sell ratings.

What is Amgen Inc’s price target?

The average price target for Amgen Inc is 323.47. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $405.00 ,the lowest forecast is $272.00. The average price target represents 15.45% Increase from the current price of $280.19.

What do analysts say about Amgen Inc?

Amgen Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of AMGN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Amgen (AMGN) Stock Forecast & Price Target

AMGN Analyst Ratings

AMGN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Amgen

AMGN Analyst Recommendation Trends

AMGN Financial Forecast

AMGN Earnings Forecast

AMGN Sales Forecast

AMGN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts